Utidelone Combined With Bevacizumab in the Treatment of ≥ 2 Lines of HER-2 Negative Advanced Breast Cancer
Henan Cancer Hospital
Henan Cancer Hospital
Institut National de la Santé Et de la Recherche Médicale, France
The Royal Wolverhampton Hospitals NHS Trust
Norwegian Institute of Public Health
Norwegian Institute of Public Health
Vastra Gotaland Region
Vastra Gotaland Region
Institut National de la Santé Et de la Recherche Médicale, France
Vastra Gotaland Region
Başakşehir Çam & Sakura City Hospital
Umraniye Education and Research Hospital
Fundació d'investigació Sanità ria de les Illes Balears
Institute for Clinical and Experimental Medicine
National Hepatology & Tropical Medicine Research Institute
National Cancer Center, Korea
Vastra Gotaland Region
The Royal Wolverhampton Hospitals NHS Trust
Sheba Medical Center
Anhui Provincial Hospital
Azienda Sanitaria Locale di Asti
The Royal Wolverhampton Hospitals NHS Trust
National Cancer Center, Korea
Henan Cancer Hospital
Instituto Nacional de Cancer, Brazil
Tuen Mun Hospital
Kayseri City Hospital
Henan Cancer Hospital
Linkoeping University
Moscow Regional Oncological Dispensary
ANRS, Emerging Infectious Diseases
Henan Cancer Hospital
University Hospital, Angers
University Hospital, Angers
ANRS, Emerging Infectious Diseases
Fundació d'investigació Sanità ria de les Illes Balears
Nanchong Central Hospital
Nanchong Central Hospital
Henan Cancer Hospital
Henan Cancer Hospital
Nanchong Central Hospital
Nanchong Central Hospital
Nanchong Central Hospital
Nanchong Central Hospital
Ankara Etlik City Hospital
Sheba Medical Center
Sorlandet Hospital HF
University Hospital, Angers
Fujian Cancer Hospital
Luxembourg Institute of Health
Health Institutes of Turkey